Literature DB >> 33210159

Influence of formulation and route of administration on ketamine's safety and tolerability: systematic review.

Paul Glue1, Bruce Russell2, Natalie J Medlicott2.   

Abstract

PURPOSE: Ketamine has rapid-onset antidepressant effects in patients with treatment-resistant depression. Common side effects include dissociation (a sense of detachment from reality) and increases in systolic and diastolic blood pressure. The objective of this structured review was to examine the effect of ketamine formulation and route of administration on its pharmacokinetics, safety and tolerability, to identify formulation characteristics and routes of administration that might minimise side effects.
METHODS: This was a structured review of published ketamine pharmacokinetics, safety and tolerability data for any ketamine formulation. The ratio of ketamine:norketamine was calculated from reported Cmax values, as a measure of first pass metabolism. The effect of formulation and route of administration on safety was evaluated by measuring mean changes in systolic blood pressure and tolerability by changes in dissociation ratings. Data were correlated using Spearman's method.
RESULTS: A total of 41 treatment arms were identified from 21 publications, and included formulation development studies in healthy volunteers, and studies in clinical populations (patients undergoing anaesthesia, or being treated for pain or depression). Ketamine:norketamine ratios were strongly positively correlated with change in dissociation ratings (r = 0.89) and change in blood pressure (r = 0.96), and strongly negatively correlated with ketamine Tmax (r = - 0.87; p < 0.00001 for all). Ketamine Tmax strongly positively correlated with a change in dissociation ratings (r = - 0.96) and change in blood pressure (r = - 0.99; p < 0.00001 for all).
CONCLUSION: Ketamine formulations that maximize first pass metabolism and delay Tmax will be better tolerated and safer than formulations which lack those characteristics.

Entities:  

Keywords:  Dissociation; First pass metabolism; Ketamine formulation; Pharmacokinetics; Safety

Year:  2020        PMID: 33210159     DOI: 10.1007/s00228-020-03047-z

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  21 in total

1.  Measurement of dissociative states with the Clinician-Administered Dissociative States Scale (CADSS).

Authors:  J D Bremner; J H Krystal; F W Putnam; S M Southwick; C Marmar; D S Charney; C M Mazure
Journal:  J Trauma Stress       Date:  1998-01

2.  Esketamine for Treatment-Resistant Depression - First FDA-Approved Antidepressant in a New Class.

Authors:  Jean Kim; Tiffany Farchione; Andrew Potter; Qi Chen; Robert Temple
Journal:  N Engl J Med       Date:  2019-05-22       Impact factor: 91.245

3.  (R,S)-Ketamine metabolites (R,S)-norketamine and (2S,6S)-hydroxynorketamine increase the mammalian target of rapamycin function.

Authors:  Rajib K Paul; Nagendra S Singh; Mohammed Khadeer; Ruin Moaddel; Mitesh Sanghvi; Carol E Green; Kathleen O'Loughlin; Marc C Torjman; Michel Bernier; Irving W Wainer
Journal:  Anesthesiology       Date:  2014-07       Impact factor: 7.892

4.  Placebo-controlled pilot trial testing dose titration and intravenous, intramuscular and subcutaneous routes for ketamine in depression.

Authors:  C K Loo; V Gálvez; E O'Keefe; P B Mitchell; D Hadzi-Pavlovic; J Leyden; S Harper; A A Somogyi; R Lai; C S Weickert; P Glue
Journal:  Acta Psychiatr Scand       Date:  2016-03-30       Impact factor: 6.392

5.  Repeated oral ketamine for out-patient treatment of resistant depression: randomised, double-blind, placebo-controlled, proof-of-concept study.

Authors:  Yoav Domany; Maya Bleich-Cohen; Ricardo Tarrasch; Roi Meidan; Olga Litvak-Lazar; Nadav Stoppleman; Shaul Schreiber; Miki Bloch; Talma Hendler; Haggai Sharon
Journal:  Br J Psychiatry       Date:  2018-09-24       Impact factor: 9.319

Review 6.  Oral ketamine for the treatment of pain and treatment-resistant depression†.

Authors:  Robert A Schoevers; Tharcila V Chaves; Sonya M Balukova; Marije aan het Rot; Rudie Kortekaas
Journal:  Br J Psychiatry       Date:  2016-02       Impact factor: 9.319

7.  Effects of ketamine in patients with treatment-refractory generalized anxiety and social anxiety disorders: Exploratory double-blind psychoactive-controlled replication study.

Authors:  Paul Glue; Shona Neehoff; Amandine Sabadel; Lucy Broughton; Martin Le Nedelec; Shabah Shadli; Neil McNaughton; Natalie J Medlicott
Journal:  J Psychopharmacol       Date:  2019-09-17       Impact factor: 4.153

Review 8.  Effects of Low-Dose and Very Low-Dose Ketamine among Patients with Major Depression: a Systematic Review and Meta-Analysis.

Authors:  Ying Xu; Maree Hackett; Gregory Carter; Colleen Loo; Verònica Gálvez; Nick Glozier; Paul Glue; Kyle Lapidus; Alexander McGirr; Andrew A Somogyi; Philip B Mitchell; Anthony Rodgers
Journal:  Int J Neuropsychopharmacol       Date:  2016-04-20       Impact factor: 5.176

9.  Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development.

Authors:  Eduardo Ekman Schenberg
Journal:  Front Pharmacol       Date:  2018-07-05       Impact factor: 5.810

10.  NMDAR inhibition-independent antidepressant actions of ketamine metabolites.

Authors:  Panos Zanos; Ruin Moaddel; Patrick J Morris; Polymnia Georgiou; Jonathan Fischell; Greg I Elmer; Manickavasagom Alkondon; Peixiong Yuan; Heather J Pribut; Nagendra S Singh; Katina S S Dossou; Yuhong Fang; Xi-Ping Huang; Cheryl L Mayo; Irving W Wainer; Edson X Albuquerque; Scott M Thompson; Craig J Thomas; Carlos A Zarate; Todd D Gould
Journal:  Nature       Date:  2016-05-04       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.